Combining machine and nanoparticles for better transplant outcome

November 30, 2017 by William Weir, Yale University
An example of nanoparticle accumulations in a biopsy taken from a human kidney stained with vasculature. The vascular-targeted nanoparticles are in red; control non-targeted particles are in green. Credit: Jenna DiRito and Gregory T. Tietjen

By combining the use of drug-carrying nanoparticles with an organ-preserving machine, Yale researchers have developed a procedure that could help improve long-term outcomes for transplant recipients.

A technology known as ex vivo normothermic machine perfusion (NMP) has emerged in recent years as a means of keeping a "alive" outside the body before implantation. The process involves pumping warm, oxygenated through an organ removed from a deceased donor. This helps repair damage to the organ and gives doctors time to assess the quality of the organ. It has also helped increase the number of organs suitable for transplant.

In collaboration with researchers from the University of Cambridge, the Yale researchers are working to expand the technology's rehabilitation abilities with a nanoparticle-based drug delivery system that can deliver a variety of treatments directly to critical targets in a human kidney while it is still in the device. Their results are published today in Science Translational Medicine.

The Yale team, from the School of Medicine and the School of Engineering and Applied Sciences, focused specifically on treating the organ's vascular . These , which line the surface of blood cells, are the first point of contact with a recipient's immune system after the transplant and are critical to the body's acceptance of the organ. Treating these cells directly with drugs that temporarily block the inflammatory signaling to the recipient's immune system allows the graft time to heal and increases the transplant's chances for long-term success. It could also decrease the chance of infection by easing the systemic immunosuppression following transplant, said the researchers.

Endothelial cells are considered an ideal target because they are readily accessible while the organ is on the machine and because alterations in these cells alert the host's immune system that the organ is foreign and to any damage the organ may have, said one of the project's leaders, Jordan Pober, the Bayer Professor of Translational Medicine and vice-chair of immunobiology. Both signals can trigger rejection.

"We know a lot about what these changes in the endothelium are, and how to mask them to reduce rejection," Pober said.

Combining machine and nanoparticles for better transplant outcome
Diagram of the drug-carrying nanoparticle (bottom left); image of a biopsy taken from a human kidney stained with vasculature (top right). The highlighted and enlarged image is an example of nanoparticle accumulations. The vascular-targeted nanoparticles are in red; control non-targeted particles are in green. Credit: Jenna DiRito and Gregory T. Tietjen

To target the cells, the researchers coated nanoparticles developed in the lab of Mark Saltzman, the Goizueta Foundation Professor of Biomedical Engineering, Chemical & Environmental Engineering & Physiology, with an antibody that targets CD31, a protein abundant in the endothelium. These particles, along with a control group of non-targeted particles, were injected into the perfusion device while its fluid was passing through a donor kidney for periods of four to six hours.

"For these studies, we produced antibody-coated nanoparticles from polymers that are well known to be safe in humans, so we anticipate that this technology can be rapidly translated into clinical practice," said Saltzman, another leader of the project. Saltzman also is a member of the Yale Cancer Center. "We have previously shown that these nanoparticles release agents slowly over time, so the effect of the treatment could last well after the organ transplantation is complete."

They found that, on average, the accumulation of targeted particles around endothelial cells could reach as much as two to five times higher than the control group. In certain regions of some of the more well-perfused kidneys, though, the accumulations were much higher, with levels exceeding 10 times that of the control particles.

The researchers kept track of the accumulations using a two-color quantitative microscopy-based approach. The CD31-targeted particles were loaded with red fluorescent dye and the control particles were loaded with green dye. With the microscopy setup, the ratio of red-to-green signal was a reliable indicator of the intensities of the two particles.

In addition to successfully targeting , the research represents another breakthrough: the development of a platform for studying such drug delivery systems on human organs.

"It's already very difficult getting where they are needed following systemic delivery, and even if you can do that in an animal, the conditions are very likely to be different in a person," said Gregory Tietjen, assistant professor of surgery and first author of the paper. Tietjen, who has opened a new lab focused on using the ex vivo perfusion platform to develop more precise nanomedicines, said he is "excited about having this infrastructure we developed to do this kind of preclinical, quantitative work in human organs."

"We think it can not only provide new therapeutic strategies for , but it also has the potential to provide new insights for systemic ."

Explore further: Drug could cut transplant rejection

More information: G.T. Tietjen el al., "Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aam6764

Related Stories

Drug could cut transplant rejection

November 21, 2017
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...

MHC class II molecules on graft endothelium promote acute rejection

January 21, 2016
A limitation of organ transplant is acute rejection of the graft by the host immune system. Graft rejection is mediated by the development of CD8+ cytotoxic T cells that target donor MHC class I molecules, and in animal models, ...

Discovery could provide new prevention, treatment option for organ transplant rejection

August 24, 2016
An international team led by researchers from the University of Pittsburgh School of Medicine found that targeting certain donor cells lowered the risk of organ rejection in mice that underwent kidney and heart transplants. ...

Recommended for you

Deep space radiation treatment reboots brain's immune system

May 21, 2018
Planning a trip to Mars? You'll want to remember your anti-radiation pills.

Receptor proteins that respond to nicotine may help fat cells burn energy

May 21, 2018
The same proteins that moderate nicotine dependence in the brain may be involved in regulating metabolism by acting directly on certain types of fat cells, new research from the University of Michigan Life Sciences Institute ...

Atomic-level study reveals why rare disorder causes sudden paralysis

May 21, 2018
A rare genetic disorder in which people are suddenly overcome with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes, researchers at the University of ...

New era for blood transfusions through genome sequencing

May 18, 2018
Most people are familiar with A, B, AB and O blood types, but there are hundreds of additional blood group "antigens" on red blood cells—substances that can trigger the body's immune response—that differ from person to ...

Robots grow mini-organs from human stem cells

May 17, 2018
An automated system that uses robots has been designed to rapidly produce human mini-organs derived from stem cells. Researchers at the University of Washington School of Medicine in Seattle developed the new system.

Scientists uncover a new face of a famous protein, SWI2/SNF2 ATPase

May 17, 2018
A team of Texas A&M and Texas A&M AgriLife Research scientists now have a deeper understanding of a large switch/sucrose non-fermentable (SWI/SNF) protein complex that plays a pivotal role in plant and human gene expression ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.